Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Lilly

FY revenues up 6%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly

4Q Revenues: $5.6 billion (+7%)

4Q Earnings:  $771.8 million (+61%)

FY Revenues: $21.2 billion (+6%)

FY Earnings: $2.7 billion (+14%)

Comments: Growth for the year was primarily driven by Trulicity ($926 million, up from $249 million FY15) and other new pharmaceutical products, including Cyramza ($614 million up 60%), Jardiance ($202 million, up from $60 million FY15) and Taltz ($113 million), as well as Humalog ($2.8 billion, down 3%) and Erbitux ($687 million, up 42%, due to the transfer of commercialization rights in North America to Lilly). The volume increases were partially offset by the impact of the loss of exclusivity for Cymbalta (down 9% to $931 million) in Europe and Canada, Zyprexa (down 23% to $725 million) in Japan, and Alimta ($2.3 billion, down 8%) in several countries. Cialis sales were $2.5 billion, up 7%. In 2016, the company recognized an acquired in-process R&D charge of $30 million associated with the agreement with AstraZeneca to co-develop MEDI1814.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters